-
Poultry Science Dec 2021Low fertilization rate is the main reason to limit the development of artificial insemination (AI) technology in ducks. However, the libido of male livestock has been...
Low fertilization rate is the main reason to limit the development of artificial insemination (AI) technology in ducks. However, the libido of male livestock has been confirmed to be related to semen quality and fertilization rate, and we found that the libido of drakes was different. Thus, the research on the libido of drakes may be the key to further develop and apply AI technology. In this research, we established the first scoring standard for libido evaluation in drakes based on the performance of drakes during training period. Phenotypically, the body weight of high libido group was lighter than that of the other groups, while the weight of testis and epididymis in the high libido group was higher than that in the low libido group. Furthermore, we constructed the first expression profile of hypothalamus, pituitary, testis, and epididymis of drakes with high or low libido. There were 2, 1822, 214, and 892 differentially expressed genes (DEGs) in hypothalamus, pituitary, testis, and epididymis. The expression and sequence of Translocation Associated Membrane Protein 2 (TRAM2) were different in high and low libido drakes, indicating that it may be a candidate gene related to drake's libido. The estrogen, prolactin, and oxytocin signaling pathways were all activated in the pituitary of the low libido group. Meanwhile, the metabolic and oxidative phosphorylation pathways were enriched by DEGs in pituitary, testis and epididymis. Our research reveals that the difference in metabolic may cause changes in body weight of drakes, resulting in altered hormone levels and oxidative phosphorylation of gonad, which negatively affects libido and spermatogenesis in drakes. These results provide novel insights into the avian libido and will help better understand the underlying molecular mechanisms.
Topics: Animals; Chickens; Libido; Male; Phenotype; Semen Analysis; Testis
PubMed: 34700098
DOI: 10.1016/j.psj.2021.101503 -
CMAJ : Canadian Medical Association... Sep 2016Physicians diagnose and treat suspected hypogonadism in older men by extrapolating from the defined clinical entity of hypogonadism found in younger men. We conducted a... (Review)
Review
BACKGROUND
Physicians diagnose and treat suspected hypogonadism in older men by extrapolating from the defined clinical entity of hypogonadism found in younger men. We conducted a systematic review to estimate the accuracy of clinical symptoms and signs for predicting low testosterone among aging men.
METHODS
We searched the MEDLINE and Embase databases (January 1966 to July 2014) for studies that compared clinical features with a measurement of serum testosterone in men. Three of the authors independently reviewed articles for inclusion, assessed quality and extracted data.
RESULTS
Among 6053 articles identified, 40 met the inclusion criteria. The prevalence of low testosterone ranged between 2% and 77%. Threshold testosterone levels used for reference standards also varied substantially. The summary likelihood ratio associated with decreased libido was 1.6 (95% confidence interval [CI] 1.3-1.9), and the likelihood ratio for absence of this finding was 0.72 (95% CI 0.58-0.85). The likelihood ratio associated with the presence of erectile dysfunction was 1.5 (95% CI 1.3-1.8) and with absence of erectile dysfunction was 0.83 (95% CI 0.76-0.91). Of the multiple-item instruments, the ANDROTEST showed both the most favourable positive likelihood ratio (range 1.9-2.2) and the most favourable negative likelihood ratio (range 0.37-0.49).
INTERPRETATION
We found weak correlation between signs, symptoms and testosterone levels, uncertainty about what threshold testosterone levels should be considered low for aging men and wide variation in estimated prevalence of the condition. It is therefore difficult to extrapolate the method of diagnosing pathologic hypogonadism in younger men to clinical decisions regarding age-related testosterone decline in aging men.
Topics: Adult; Aged; Aged, 80 and over; Aging; Erectile Dysfunction; Humans; Hypogonadism; Libido; Likelihood Functions; Male; Middle Aged; Prevalence; Testosterone
PubMed: 27325129
DOI: 10.1503/cmaj.150262 -
Current Opinion in Supportive and... Sep 2015Young women (<45 years of age) diagnosed with breast cancer face increased risk of sexual dysfunction as a result of their cancer-directed treatment. We will review the... (Review)
Review
PURPOSE OF REVIEW
Young women (<45 years of age) diagnosed with breast cancer face increased risk of sexual dysfunction as a result of their cancer-directed treatment. We will review the recent literature examining this critical challenge and discuss current efforts to address sexual dysfunction.
RECENT FINDINGS
In the period since 2013, the literature has focused on sexual issues that result from the premature onset of menopausal symptoms and changes in sexual health following breast surgery. The impact of premature menopause in young women with breast cancer is profound and can affect all aspects of the sexual experience, from desire to function, and quality of life. Furthermore, the surgical treatment of breast cancer also has significant implications with respect to sexual desire and body image. There is a paucity of sexual health intervention for this population, though recent efforts suggest that sexual health outcomes may be improved if women are offered the appropriate intervention opportunities. However, the sexual function of young breast cancer patients is an under-discussed and under-treated health issue that warrants greater research and clinical focus.
SUMMARY
Further intervention trials must be completed in this population of young women for whom sexual function plays such a critical role in their personal and relationship well being.
Topics: Adult; Antineoplastic Agents; Body Image; Breast Neoplasms; Communication; Estrogen Antagonists; Female; Humans; Libido; Mastectomy; Menopause, Premature; Patient Education as Topic; Quality of Life
PubMed: 26155020
DOI: 10.1097/SPC.0000000000000156 -
Sexual Medicine Reviews Apr 20195-Alpha reductase inhibitors (5-ARIs) are widely used in the treatment of benign prostatic hyperplasia (BPH) and androgenic alopecia (AGA). (Review)
Review
INTRODUCTION
5-Alpha reductase inhibitors (5-ARIs) are widely used in the treatment of benign prostatic hyperplasia (BPH) and androgenic alopecia (AGA).
AIM
To examine all available data on the effects of 5-ARIs on sexual functioning in AGA treatment and to assess whether 5-ARIs increase the risk of sexual dysfunction.
METHODS
A literature review of publications at PubMed related to the subject was used.
MAIN OUTCOME MEASURE
We assessed erectile dysfunction, ejaculation impairment, and decreased libido.
RESULTS
5-ARIs may cause side effects such as erectile dysfunction, ejaculation problems, and decreased libido in patients. Their long-term impact and precise mechanism have not been clarified. Data from studies on 5-ARIs are important for drug selection and patient counseling. More training and awareness is needed for clinicians and patients to recover many patients from sexual adverse effects.
CONCLUSION
5-ARIs used in the treatment of AGA have well-defined side effects, which can negatively affect sexual life. It is unknown and unpredictable which men using these drugs may be subject to these side effects and when these effects may appear. Studies have been insufficient to provide a clear answer to this question. Coskuner ER, Ozkan B, Culha MG. Sexual Problems of Men With Androgenic Alopecia Treated With 5-Alpha Reductase Inhibitors. Sex Med Rev 2019;7:277-282.
Topics: 5-alpha Reductase Inhibitors; Alopecia; Dutasteride; Ejaculation; Erectile Dysfunction; Finasteride; Humans; Libido; Male; Sexual Dysfunction, Physiological; Sexual Dysfunctions, Psychological
PubMed: 30301703
DOI: 10.1016/j.sxmr.2018.07.003 -
The American Journal of Nursing Mar 2016
Topics: Adult; Aged; Benzimidazoles; Ethanol; Female; Humans; Hypotension; Libido; Male; Middle Aged; Orgasm; Sexual Dysfunctions, Psychological
PubMed: 26914033
DOI: 10.1097/01.NAJ.0000481261.79494.31 -
Current Opinion in Psychology Aug 2023Sex is one unique way people can show responsiveness in romantic relationships. Being and having a sexually responsive partner-who is understanding and motivated to make... (Review)
Review
Sex is one unique way people can show responsiveness in romantic relationships. Being and having a sexually responsive partner-who is understanding and motivated to make sexual compromises-is associated with sexual desire maintenance, sexual satisfaction, and relationship quality, especially when partners have different sexual interests or are coping with sexual issues. But, if being responsive to a partner's sexual needs involves self-neglect, sexual responsiveness no longer has these benefits and can be costly. Future research on sexual responsiveness should involve the development of a comprehensive measure incorporating lay perceptions and considering gendered sexual expectations, and an investigation of the balance between sexual autonomy and responsiveness in relationships.
Topics: Humans; Sexual Partners; Sexual Behavior; Libido; Adaptation, Psychological; Personal Satisfaction
PubMed: 37423039
DOI: 10.1016/j.copsyc.2023.101644 -
Menopause (New York, N.Y.) Jul 2023Testosterone is an important evidence-based therapy for hypoactive sexual desire disorder (HSDD) in postmenopausal women. Clinical practice guidelines based on the most... (Meta-Analysis)
Meta-Analysis
Testosterone is an important evidence-based therapy for hypoactive sexual desire disorder (HSDD) in postmenopausal women. Clinical practice guidelines based on the most comprehensive meta-analysis of benefits and risks of testosterone therapy to date state that the sole evidence-based indication for testosterone therapy is HSDD in postmenopausal women. The guidelines also provide recommendations regarding identification of patients, dosing, monitoring, and follow-up. This Practice Pearl will discuss evidence-based testosterone therapy for management of HSDD in postmenopausal women.
Topics: Female; Humans; Testosterone; Postmenopause; Sexual Dysfunctions, Psychological; Administration, Cutaneous; Libido
PubMed: 37314872
DOI: 10.1097/GME.0000000000002190 -
Medicine and Science in Sports and... Jul 2017This article aimed to study the associations between aspects of endurance exercise training and sexual libido in healthy men using a cross-sectional online survey study...
PURPOSE
This article aimed to study the associations between aspects of endurance exercise training and sexual libido in healthy men using a cross-sectional online survey study design.
METHODS
A developed online survey questionnaire was used. The questionnaire was based on preexisting validated questionnaires and was used to assess elements of physical characteristics, exercise training habits, and libido of participants (n = 1077). Three evidence-based categories were created for the primary outcome of total libido score and low, normal, and high-response category sets. The high and normal categories were combined to form a high/normal score group, and the low category formed a low score group. Odds ratio (OR) values were calculated to examine group categorization.
RESULTS
Age, training intensity, and training duration of participants had significant (P < 0.02) univariate relationships, with libido scores, and were thus included in the multivariate model. In the multivariate model, training intensity (P < 0.0001) and duration (P < 0.002) components were the most significantly associated with libido group designation (high/normal vs low). Participants with the lowest (OR = 6.9, 95% confidence interval [CI] = 2.6-17.9) and mid-range training intensities (OR = 2.8, 95% CI = 1.4-5.3) had greater odds of high/normal libido state than those with the highest training intensity. Participants with the shorter (OR = 4.1, 95% CI = 1.6-10.0) and mid-range training durations (OR = 2.5, 95% CI = 1.3-4.8) at their current intensity also had greater odds of high/normal libido score than those with a greatest duration.
CONCLUSION
Exposure to higher levels of chronic intense and greater durations of endurance training on a regular basis is significantly associated with a decreased libido scores in men. Clinicians who treat male patients for sexual disorders and/or council couples on infertility issues should consider the degree of endurance exercise training a man is performing as a potential complicating factor.
Topics: Adolescent; Adult; Cross-Sectional Studies; Humans; Libido; Male; Middle Aged; Physical Conditioning, Human; Physical Endurance; Surveys and Questionnaires; Time Factors; Young Adult
PubMed: 28195945
DOI: 10.1249/MSS.0000000000001235 -
Hormones and Behavior May 2017Hormones orchestrate and coordinate human female sexual development, sexuality, and reproduction in relation to three types of phenotypic changes: life history... (Review)
Review
Hormones orchestrate and coordinate human female sexual development, sexuality, and reproduction in relation to three types of phenotypic changes: life history transitions such as puberty and childbirth, responses to contextual factors such as caloric intake and stress, and cyclical patterns such as the ovulatory cycle. Here, we review the endocrinology underlying women's reproductive phenotypes, including sexual orientation and gender identity, mate preferences, competition for mates, sex drive, and maternal behavior. We highlight distinctive aspects of women's sexuality such as the possession of sexual ornaments, relatively cryptic fertile windows, extended sexual behavior across the ovulatory cycle, and a period of midlife reproductive senescence-and we focus on how hormonal mechanisms were shaped by selection to produce adaptive outcomes. We conclude with suggestions for future research to elucidate how hormonal mechanisms subserve women's reproductive phenotypes.
Topics: Endocrinology; Female; Gender Identity; Gonadal Steroid Hormones; Humans; Libido; Marriage; Reproduction; Reproductive Behavior; Sexual Behavior; Sexual Maturation; Sexual Partners; Sexuality
PubMed: 27866819
DOI: 10.1016/j.yhbeh.2016.11.012 -
Minerva Obstetrics and Gynecology Jun 2022There are different types of female sexual dysfunctions (FSDs), and FSD in general has a high prevalence worldwide. Studies of FSD should consider it as a multifactorial... (Review)
Review
INTRODUCTION
There are different types of female sexual dysfunctions (FSDs), and FSD in general has a high prevalence worldwide. Studies of FSD should consider it as a multifactorial disorder that has biological, psychological, environmental, and relational aspects. In this review we discuss the available therapeutic interventions for FSD.
EVIDENCE ACQUISITION
For the current narrative review the PubMed database was searched to identify all publications up to 30 March 2021 that were systematic reviews and meta-analyses which examined therapeutic interventions for FSDs based on the diagnostic classifications of ICD-10 and ICD-11.
EVIDENCE SYNTHESIS
Thirty systematic reviews and meta-analyses were included in this review. Hormone therapy (HT) and testosterone are effective to improve sexual desire in menopausal women. In these women HT and ospemiphene may improve pain during intercourse. Flibanserin may improve sexual desire and may reduce desire-related distress in premenopausal women. Bremelanotide is effective to improve desire, arousal, and orgasm scores. Evidence are still limited on the efficacy of psychoactive drugs, phosphodiesterase type 5 (PDE5), oxytocin, herbal drugs, and tibolone to treat FSDs. Psychological interventions such as cognitive-behavior therapy, mindfulness training, sensate focus, bibliotherapy are effective for the management of several different FSDs.
CONCLUSIONS
The management of FSDs may require multidisciplinary and interdisciplinary approaches. Pharmacological and nonpharmacological interventions appears to have potential as a treatment for FSDs, but there are currently no gold standards regarding recommended treatment modalities, and the duration, frequency, and intensity of therapy sessions.
Topics: Female; Humans; Libido; Orgasm; Premenopause; Prevalence; Sexual Dysfunctions, Psychological
PubMed: 35147017
DOI: 10.23736/S2724-606X.22.04966-1